Melbourne, Australia, 22 January 2020: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, is pleased to announce the first healthy volunteer has been dosed as part of its Phase I single ascending dose study.
The Phase I trial is being conducted at Nucleus Network in Melbourne and is evaluating the safety and tolerability of OCX063 through single and repeated administration across a range of doses.
OccuRx is dedicated to identifying and validating novel targets that treat and prevent fibrosis that lead to disease progression and end organ failure.
OCX063, the drug molecule being tested, is being developed as a first-in-class oral therapy for the treatment for both kidney and ocular diseases. OCX063, is an orally available, small molecule drug with the potential to prevent the growth of new and abnormal blood vessels and reduce inflammation.
“We’re excited to dose the first patient as part of our Phase I healthy volunteer study for our lead anti-fibrotic drug candidate, OCX063. The dosing of our first patient marks the start of our journey towards developing therapies that have the potential to change how we treat and prevent fibrosis.” said Professor Darren Kelly, Executive Chair of OccuRx.
The first patient milestone marks the commencement of the Phase I study which is expected to be completed in Q3 of this year.
